Obsidian Therapeutics (NASDAQ:OBX) Sees Large Increase in Short Interest

Obsidian Therapeutics (NASDAQ:OBX) was the recipient of a large growth in short interest during the month of August. As of August 31st, there was short interest totaling 81,457 shares, a growth of 125.6% from the August 15th total of 36,102 shares. Based on an average daily trading volume, of 227,768 shares, the short-interest ratio is presently 0.4 days. Approximately 0.1% of the shares of the company are short sold.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Lifesci Capital assumed coverage on shares of Obsidian Therapeutics in a research note on Tuesday, August 18th. They set an “outperform” rating and a $43.00 price target on the stock. William Blair initiated coverage on Obsidian Therapeutics in a research note on Wednesday. They set an “outperform” rating for the company. TD Cowen began coverage on shares of Obsidian Therapeutics in a research report on Thursday, August 6th. They set a “buy” rating for the company. Weiss Ratings started coverage on shares of Obsidian Therapeutics in a report on Wednesday, September 2nd. They set a “sell (d-)” rating for the company. Finally, Zacks Research raised Obsidian Therapeutics to a “hold” rating in a research note on Thursday, August 6th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Obsidian Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $42.50.

Obsidian Therapeutics Trading Up 4.6%

Shares of Obsidian Therapeutics stock traded up $0.81 during trading on Monday, hitting $18.61. The company’s stock had a trading volume of 67,570 shares, compared to its average volume of 190,342. Obsidian Therapeutics has a 52 week low of $14.57 and a 52 week high of $49.97.

Obsidian Therapeutics Company Profile

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.